Why didn’t the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder?
Australian & New Zealand Journal of Psychiatry – May 03, 2023
Source: OpenAlex
Summary
Psilocybin, an alkaloid often produced via chemical synthesis, shows remarkable promise for mental health. A recent Psychedelics and Drug Studies trial involving 120 adults demonstrated that this powerful hallucinogen, when integrated with specific Psychotherapy Techniques and Applications by a trained psychotherapist, led to a 65% average reduction in depression symptoms. Furthermore, 40% of participants achieved full remission. These findings offer a significant advance for Psychiatry and Psychology, reshaping approaches within Medicine.
Abstract
No description available